Literature DB >> 32986447

Assessment of Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles' Biocompatibility with Endothelial Cells in Vitro and Delivery of an Anti-Inflammatory Drug.

Aikaterini Berdiaki1, Emmanouela Perisynaki1, Antonios Stratidakis2,3, Pavel P Kulikov4,5, Andrey N Kuskov4, Polychronis Stivaktakis3, Petra Henrich-Noack6, Anna L Luss4, Mikhail M Shtilman4, George N Tzanakakis1,7, Aristidis Tsatsakis3,4, Dragana Nikitovic1.   

Abstract

Nanoparticles (NPs) produced from amphiphilic derivatives of poly-N-vinylpyrrolidone (Amph-PVP), composed of various molecular weight polymeric hydrophilic fragments linked into hydrophobic n-alkyl chains of varying lengths, were previously shown to exert excellent biocompatibility. Although routes of administration can be different, finally, most nanosystems enter the blood circulation or lymphatic vessels, and by this, they establish direct contact with endothelial cells. In this study, Amph-PVP NPs and fluorescently labeled Amph-PVP-based NPs, namely "PVP" NPs (Amph-PVP-NPs (6000 Da) unloaded) and "F"-NPs (Amph-PVP-NPs (6000 Da) loaded with fluorescent FITC), were synthesized to study Amph-PVP NPs interactions with HMEC-1 endothelial cells. PVP NPs were readily uptaken by HMEC-1 cells in a concentration-dependent manner, as demonstrated by immunofluorescence imaging. Upon uptake, the FITC dye was localized to the perinuclear region and cytoplasm of treated cells. The generation of lipopolysaccharide (LPS)-induced activated endothelium model revealed an increased uptake of PVPNPs, as shown by confocal microscopy. Both unloaded PVP NPs and F-NPs did not affect EC viability in the 0.01 to 0.066 mg/mL range. Furthermore, we focused on the potential immunological activation of HMEC-1 endothelial cells upon PVPNPs treatment by assessing the expression of their E-Selectin, ICAM-1, and VCAM-1 adhesion receptors. None of the adhesion molecules were affected by NP treatments of both activated by LPS and nonactivated HMEC-1 cells, at the utilized concentrations (p = NS). In this study, PVP (6000 Da) NPs were used to encapsulate indomethacin, a widely used anti-inflammatory drug. The synthesized drug carrier complex did not affect HMEC-1 cell growth and expression of E-selectin, ICAM-1, and VCAM-1 adhesion receptors. In summary, PVP-based NPs are safe for use on both basal and activated endothelium, which more accurately mimics pathological conditions. Amph-PVP NPs are a promising drug delivery system.

Entities:  

Keywords:  amphiphilic polymer; assessment; endothelial cells; fluorescent probes; immunological activation; nanoparticle; poly-N-vinylpyrrolidone; viability

Year:  2020        PMID: 32986447     DOI: 10.1021/acs.molpharmaceut.0c00667

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  3 in total

1.  Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles as Carriers for Nonsteroidal, Anti-Inflammatory Drugs: Pharmacokinetic, Anti-Inflammatory, and Ulcerogenic Activity Study.

Authors:  Andrey Kuskov; Dragana Nikitovic; Aikaterini Berdiaki; Mikhail Shtilman; Aristidis Tsatsakis
Journal:  Pharmaceutics       Date:  2022-04-24       Impact factor: 6.525

2.  The Anti-Inflammatory Effect of Nanoarchaeosomes on Human Endothelial Cells.

Authors:  Nancy Charó; Horacio Jerez; Silvio Tatti; Eder Lilia Romero; Mirta Schattner
Journal:  Pharmaceutics       Date:  2022-03-29       Impact factor: 6.525

Review 3.  Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Authors:  Aikaterini Berdiaki; Monica Neagu; Eirini-Maria Giatagana; Andrey Kuskov; Aristidis M Tsatsakis; George N Tzanakakis; Dragana Nikitovic
Journal:  Biomolecules       Date:  2021-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.